Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
October 23, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress

Highlights advantages of IMUNON’s PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
October 19, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations

“A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association LAWRENCEVILLE, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
October 18, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
October 06, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE...
September 28, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued...
September 26, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies

Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) --...
September 13, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...
September 07, 2023 16:30 ET | Source: Imunon, Inc.

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) --...
September 05, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON to Participate in the H.C. Wainwright Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th...